편두통 : 역학 예측(-2033년)

Migraine is a prevalent neurological disorder marked by intense, debilitating headaches. It typically presents as a unilateral, pulsating, or throbbing pain that ranges from moderate to severe and is exacerbated by physical activity. Other common symptoms include nausea, vomiting, sensitivity to light (photophobia), and sensitivity to sound (phonophobia). According to the International Classification of Headache Disorders, Third Edition (ICHD-3) criteria, migraines are classified into two types based on the presence of characteristic transient focal neurological symptoms that usually precede or sometimes accompany the headache: migraine with aura and migraine without aura (Olesen, 2018). The symptoms of migraine with aura include visual disturbances such as flashing lights or lightning streaks, as well as language and speech difficulties. In some cases, one or more limbs may become numb during a migraine attack (Olesen, 2018). Migraine can be divided into four stages: prodrome, aura, attack, and postdrome. However, not everyone with migraine experiences all these stages. The duration of each stage varies both among individuals and between different migraine episodes (Goadsby et al., 2017). Based on the frequency of headaches, migraine can be classified into two types: episodic migraine, which occurs on fewer than 15 headache days per month, and chronic migraine, which occurs on 15 or more headache days per month (Buse et al., 2012; Olesen, 2018). Although the exact cause of migraine is unknown, it seems to result from various factors, including changes in the brainstem and its interactions with the trigeminal nerve, a major pain pathway. Additionally, a decrease in serotonin levels in the brain leads to the dilation of cranial blood vessels, which is considered a trigger for migraine (Goadsby et al., 2017). Genetic factors also contribute, as a family history of migraine is a common risk factor (Lateef et al., 2015).

In the 7MM, the 12-month total prevalent cases of migraine are expected to increase from 74,226,117 cases in 2023 to 75,452,770 cases in 2033, at an Annual Growth Rate (AGR) of 0.17%. In 2033, the US will have the highest number of 12-month total prevalent cases of migraine in the 7MM, with 43,904,470 cases, while Japan will have the fewest 12-month total prevalent cases with 4,002,331 cases. GlobalData epidemiologists attribute the increase in the 12-month total prevalent cases of migraine in the 7MM to population dynamics in each market.

The 12-month diagnosed prevalent cases of migraine in the 7MM are expected to increase from 32,612,840 cases in 2023 to 39,159,484 cases in 2033, at an AGR of 2.00%. In 2033, the US will have the highest number of 12-month diagnosed prevalent cases of migraine in the 7MM, with 22,229,726 cases, whereas Japan will have the fewest 12-month diagnosed prevalent cases with 1,817,962 cases.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine. The 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine are segmented by age (18 years and older), sex, and subtype (migraine with aura and migraine without aura). The report also includes the 12-month total and 12-month diagnosed prevalent cases of migraine further segmented by migraine frequency into episodic migraine and chronic migraine for both sexes and ages 18 years and older. This epidemiology forecast for migraine is supported by data obtained from peer-reviewed articles and population-based studies based on the ICHD-3 criteria. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine across these markets.

Reasons to Buy

The Migraine epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global Migraine market.
• Quantify patient populations in the global Migraine market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Migraine therapeutics in each of the markets covered.

Table of Contents

Table of Contents

1 Migraine: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities.
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology.
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods.
  • 2.4.3 12-month total prevalent cases of migraine
  • 2.4.4 12-month total prevalent cases of migraine by frequency
  • 2.4.5 12-month total prevalent cases of migraine by type
  • 2.4.6 12-month diagnosed prevalent cases of migraine
  • 2.4.7 12-month diagnosed prevalent cases of migraine by frequency
  • 2.4.8 12-month diagnosed prevalent cases of migraine by type
• 2.5 Epidemiological forecast for migraine (2023-2033)
  • 2.5.1 12-month total prevalent cases of migraine
  • 2.5.2 Age-specific 12-month total prevalent cases of migraine
  • 2.5.3 Sex-specific 12-month total prevalent cases of migraine
  • 2.5.4 12-month total prevalent cases of migraine by frequency
  • 2.5.5 12-month total prevalent cases of migraine by type
  • 2.5.6 12-month diagnosed prevalent cases of migraine
  • 2.5.7 Age-specific 12-month diagnosed prevalent cases of migraine.
  • 2.5.8 Sex-specific 12-month diagnosed prevalent cases of migraine.
  • 2.5.9 12-month diagnosed prevalent cases of migraine by frequency
  • 2.5.10 12-month diagnosed prevalent cases of migraine by type
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact.
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary research - KOLs interviewed for this report.
  • 3.2.1 KOLs.
• 3.3 Primary research - prescriber survey
• 3.4 About the authors
  • 3.4.1 Epidemiologist
  • 3.4.2 Reviewers
  • 3.4.3 Vice President of Disease Intelligence and Epidemiology
  • 3.4.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us